TheraRadar
← Back
Data updated: Jun 28, 2026

PRAXAIR INC

Pharma
Pharmaceuticals

PRAXAIR INC is a pharmaceutical company with 4 FDA-approved products.

2013
Since
4
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
4 Small Molecules

PRAXAIR INC's Key Drugs

PRAXAIR INC's core commercial portfolio centers on OXYGEN, USP, HELIUM, USP, NITROGEN, NF — its most strategically important drugs approved in the last 15 years.

OXYGEN, USP
Respiratory
Approved 2013
HELIUM, USP
Respiratory
Approved 2013
NITROGEN, NF
Other
Approved 2013
CARBON DIOXIDE, USP
Respiratory
Approved 2013

PRAXAIR INC's Recent FDA Approvals

PRAXAIR INC secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

PRAXAIR INC's Therapeutic Areas

Disease areas where PRAXAIR INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

PRAXAIR INC Pipeline Snapshot

Active clinical trials for PRAXAIR INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • OXYGEN, USP leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling